Research Square
February 23, 2026
Rotem Petranker, Norman A. S. Farb, Omer A. Syed et al.
preprint
Abstract IMPORTANCE Microdosing psilocybin may be a novel treatment for major depressive disorder (MDD). OBJECTIVE Assessing the antidepressant effects and safety of repeated low doses of psilocybin in participants diagnosed with MDD. DESIGN This was a Phase II, randomized, double-blind, placebo-controlled clinical trial. SETTING The trial was conducted from July 2022 to December 2024 at two...
BMC Psychology
February 22, 2026
Xiaoshuo Zhang, Yaping Shuai, Yuzheng Wang et al.
Abstract Background Migrant children often experience greater anxiety and depression than their local peers due to challenges in adapting to urban life. Emotional resilience and mindfulness may serve as protective factors for mental health, but their influence on migrant children’s emotional well-being is not well understood. This study explored differences in anxiety, depression, mindfulness,...
Canadian Geriatrics Journal
February 21, 2026
Mathilde Labbé, Katerina Nikolitch, Romeo Penheiro et al.
-
Journal of Clinical Medicine
February 20, 2026
Vassilis Martiadis, Fabiola Raffone, Serena Testa et al.
7 citations
Background/Objectives: Intranasal esketamine has emerged as an effective treatment for patients with treatment-resistant depression (TRD), providing rapid symptom relief when conventional antidepressant strategies fail. While its pharmacological efficacy has been demonstrated in randomized controlled trials, less attention has been paid to the organizational, relational, and multidisciplinary...
Expert Opinion on Drug Safety
February 19, 2026
Kyle Valentino, Kayla M Teopiz, Christine E. Dri et al.
1. Esketamine as monotherapy or adjunct to conventional antidepressants is proven efficacious in clinical trials in adults with treatment-resistant depression (TRD) and depression with high risk of...
AJN, American Journal of Nursing
February 19, 2026
Liz Braun, Alison Colbert
Ketamine has emerged as a promising intervention for treatment-resistant mental health disorders, such as depression, anxiety, and posttraumatic stress disorder. With rising global mental health burdens and the limitations of existing pharmacological treatments, ketamine's novel mechanism of action provides a potential alternative for individuals who have not responded to traditional therapies....
Psychiatry Research
February 19, 2026
Trisha Menon, Andy Lu, Akhilan Arulmozhi et al.
Ketamine, esketamine, rTMS and ECT are associated with reductions in SI in persons with MDD, with the strongest evidence from randomized controlled trials supporting rapid, short-term effects, particularly for ketamine and esketamine. Further characterization and differentiation of the durability of antisuicidal effects of the aforementioned interventions requires investigation in large-scale,...
medRxiv
February 19, 2026
Amanda Gow, Emily Shih, Ryan Reid et al.
preprint
Abstract Background In 2020, Oregon became the first U.S. state to establish a regulated framework for adults to access psilocybin services using naturally-derived mushroom products. No studies have examined mental health outcomes among individuals receiving psilocybin in this context. Aims To evaluate changes in self-reported symptoms of depression, anxiety, and well-being 30-days...
Translational Psychiatry
February 18, 2026
Xuefeng Xu, Huabin Wang, Shaoyu Cui et al.
Internet gaming disorder (IGD) has been recognized as a serious mental illness and is often accompanied by depression (IGD-D). An ideal treatment strategy should have effects on both the conditions. Mindfulness meditation (MM) has attracted substantial attention for the treatment of psychiatric diseases; however, its effects on IGD-D and the underlying mechanisms remain unknown. A total of 70...
Medical Science Monitor
February 18, 2026
Łukasz Grabarczyk, Sophia Rebekka Wolfermann, Hubert Oniszczuk et al.
Conventional antidepressant drugs are effective in only approximately 50% of patients with treatment-resistant depression (TRD). Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, offers a promising alternative with an exceptionally rapid antidepressant effect. Although its efficacy in the general TRD population is well established, its use in specific patient subpopulations...
Molecular Psychiatry
February 18, 2026
Marie Huc, Sara Siddiqi, Mysa Myers et al.
1 citation
Esketamine has emerged as a fast-acting antidepressant option for individuals with treatment-resistant depression (TRD). Yet, little is known about how sex-assigned-at-birth shapes symptom-specific responses to these interventions, a critical gap in the move toward precision psychiatry. To address this gap, we conducted a pooled analysis of five randomized, double-blind, placebo-controlled...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
February 18, 2026
Dimitri Henriques Daldegan-Bueno, C Donegan, Rachael Sumner et al.
1 citation
Results suggest short-term improvements in mood following microdosed LSD in people with depression, warranting confirmation in controlled trials. It provides the pharmacokinetic parameters of 8 μg of LSD in a sample of people with depression and indicates no tolerance or sensitisation to repeated microdoses of LSD, despite incremental dose titration.
Research Square
February 17, 2026
Zofia Winczewska, Magdalena Górska-ponikowska, Wiesław Jerzy Cubała
preprint
Abstract Aim of study: The antidepressant effect of ketamine may be at least partly due to its antioxidant activity. The aim of the study was to assess whether ketamine develops a protective effect on HT22 neuronal cells under conditions of oxidative stress (OS) induced by hydrogen peroxide (H 2 O 2 ). Material and methods The experiment was performed on an immortalized mouse hippocampal HT22...
Nature Medicine
February 16, 2026
David Erritzøe, Tommaso Barba, Tiffanie Benway et al.
4 citations
Major depressive disorder (MDD) is a leading cause of disability worldwide, yet many patients have inadequate responses to current treatments. Dimethyltryptamine (DMT), a serotonergic psychedelic with rapid onset and short duration, shows promise as a potential antidepressant (AD), although clinical evidence in MDD remains limited. We conducted a phase IIa, double-blind, placebo-controlled,...
BJPsych Open
February 16, 2026
Zeina Beidas, Anya Ragnhildstveit, Adam Blackman et al.
1 citation
BACKGROUND: Major depressive disorder (MDD) is the leading cause of disability worldwide, affecting roughly 322 million people. Recently, doses of psilocybin have shown promise in treating mood disorders, sparking interest in other dosing practices. According to anecdotal reports and observational studies, microdosing psilocybin yields benefits to mental health; however, rigorously controlled...
International Journal of Innovative Technologies in Social Science
February 16, 2026
Aleksandra Lejman, Rafał Bednarczyk, Natalia Bednarczyk et al.
Background: Esketamine nasal spray represents the first FDA approved treatment with a novel mechanism of action for treatment resistant depression (TRD) in decades. While its efficacy has been well established, a thorough understanding of the adverse effect profile remains essential for informed clinical decision making and optimal patient safety. We therefore undertook this systematic review...
Journal of Affective Disorders
February 15, 2026
Tomas Lindegaard, Anton Käll
Although there is increasing evidence of the efficacy of psychedelic-assisted psychotherapy (PAP) for depressive and anxiety disorders, less is known regarding how different methodological aspects affect outcomes. This study investigated the moderating impact of one or multiple dosing sessions and type of adjunctive psychotherapy on the efficacy of PAP in depression and anxiety populations....
Journal of Affective Disorders
February 14, 2026
H. Xue, Xu Yang, Shihui Kuai et al.
General anesthetics can exert significant adverse effects on the central nervous system. This study aimed to investigate whether repeated exposure to sevoflurane induces depression-like behaviors in postpartum rats. Pregnant rats were exposed to 3% sevoflurane for 2 h on gestational days 13-15. Emotional behaviors were assessed on postpartum days 1, 7, 14, and 21. Hippocampal protein levels...
European Psychiatry
February 13, 2026
Haining Ma, Huaigui Liu, Wenwei Zhang et al.
Considerable effort has been devoted to investigate the neuroimaging correlates and predictors of antidepressant response to ketamine, yet inconsistency in the location and nature of the regional brain effects makes it difficult to unify this research. Despite the revolutionary notion that psychiatric therapeutics show network-level brain representations, investigations into network...
Research Square
February 12, 2026
Jenessa N Johnston, Greg Jones, Shiyong Peng et al.
preprint
Rapid-acting antidepressants like ketamine and serotonergic psychedelics show promise for treatment-resistant depression (TRD), but the molecular mechanisms that contribute to their therapeutic effects remain unclear. Induced pluripotent stem cells (iPSCs) offer a platform to model human cortical neurons and investigate drug effects in a human-relevant system. Here, iPSCs from individuals with...